LV10962B - New peptides - Google Patents
New peptides Download PDFInfo
- Publication number
- LV10962B LV10962B LVP-95-197A LV950197A LV10962B LV 10962 B LV10962 B LV 10962B LV 950197 A LV950197 A LV 950197A LV 10962 B LV10962 B LV 10962B
- Authority
- LV
- Latvia
- Prior art keywords
- phe
- tic
- tyr
- boc
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
- C07K14/70—Enkephalins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9300012A SE9300012D0 (sv) | 1993-01-05 | 1993-01-05 | New peptides |
| PCT/SE1993/001090 WO1994015959A1 (en) | 1993-01-05 | 1993-12-20 | New peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LV10962A LV10962A (lv) | 1995-12-20 |
| LV10962B true LV10962B (en) | 1997-04-20 |
Family
ID=20388466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LVP-95-197A LV10962B (en) | 1993-01-05 | 1995-06-29 | New peptides |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5602099A (sv) |
| EP (1) | EP0678099A1 (sv) |
| JP (1) | JPH08505386A (sv) |
| KR (1) | KR960700269A (sv) |
| CN (1) | CN1096515A (sv) |
| AP (1) | AP508A (sv) |
| AU (1) | AU681372B2 (sv) |
| CA (1) | CA2152380A1 (sv) |
| CZ (1) | CZ171195A3 (sv) |
| EE (1) | EE9400326A (sv) |
| FI (1) | FI953302A (sv) |
| HU (1) | HUT72597A (sv) |
| IL (1) | IL108169A0 (sv) |
| IS (1) | IS4115A (sv) |
| LV (1) | LV10962B (sv) |
| MX (1) | MX9400255A (sv) |
| NO (1) | NO952650L (sv) |
| NZ (1) | NZ259597A (sv) |
| PL (1) | PL309778A1 (sv) |
| SE (1) | SE9300012D0 (sv) |
| SI (1) | SI9400005A (sv) |
| SK (1) | SK83995A3 (sv) |
| WO (1) | WO1994015959A1 (sv) |
| YU (1) | YU394A (sv) |
| ZA (1) | ZA9455B (sv) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112111A (en) * | 1993-12-23 | 2000-07-16 | Novo Nordisk As | Peptides having growth hormone releasing properties and pharmaceutical compositions containing them |
| IS4261A (is) * | 1994-02-21 | 1995-08-22 | Astra Aktiebolag | Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra |
| IL114046A0 (en) * | 1994-06-20 | 1995-10-31 | Astra Ab | New opioid peptide antagonists |
| RU2067000C1 (ru) * | 1994-06-29 | 1996-09-27 | Владислав Исакович Дейгин | Пептид и способ его получения |
| US6184208B1 (en) | 1994-06-29 | 2001-02-06 | Immunotech Developments Inc. | Peptide, a method for its preparation and a pharmaceutical composition containing the peptide |
| SE9402880D0 (sv) * | 1994-08-30 | 1994-08-30 | Astra Ab | New peptide derivatives |
| US5780589A (en) * | 1994-11-30 | 1998-07-14 | The United States Of America As Represented By The Department Of Health And Human Services | Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof |
| CA2216532A1 (en) * | 1995-03-29 | 1996-10-31 | S. Jane Desolms | Inhibitors of farnesyl-protein transferase |
| EP0837857A4 (en) * | 1995-03-29 | 1998-08-05 | Merck & Co Inc | FARNESYL-PROTEIN TRANSFERASE INHIBITORS |
| DE19512484A1 (de) | 1995-04-04 | 1996-10-17 | Bayer Ag | Kohlenhydratmodifizierte Cytostatika |
| SE9600769D0 (sv) * | 1996-02-28 | 1996-02-28 | Astra Ab | Compounds useful as analgesic |
| EP1001764A4 (en) * | 1997-05-29 | 2005-08-24 | Merck & Co Inc | Heterocyclic amides as cell adhesion inhibitors |
| US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
| US6703381B1 (en) | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US6306576B1 (en) * | 1999-02-19 | 2001-10-23 | Cleveland Clinic Foundation | Diagnostic methods for asthma |
| US7601739B2 (en) | 2003-08-08 | 2009-10-13 | Virgina Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases |
| CA2571710A1 (en) | 2004-06-24 | 2006-11-02 | Nicholas Valiante | Small molecule immunopotentiators and assays for their detection |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| US20060069086A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| WO2015200828A1 (en) * | 2014-06-27 | 2015-12-30 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Conjugates for immunotherapy |
-
1993
- 1993-01-05 SE SE9300012A patent/SE9300012D0/sv unknown
- 1993-12-20 CA CA002152380A patent/CA2152380A1/en not_active Abandoned
- 1993-12-20 AU AU58448/94A patent/AU681372B2/en not_active Ceased
- 1993-12-20 HU HU9502041A patent/HUT72597A/hu unknown
- 1993-12-20 CZ CZ951711A patent/CZ171195A3/cs unknown
- 1993-12-20 EP EP94904365A patent/EP0678099A1/en not_active Withdrawn
- 1993-12-20 JP JP6515914A patent/JPH08505386A/ja active Pending
- 1993-12-20 SK SK839-95A patent/SK83995A3/sk unknown
- 1993-12-20 NZ NZ259597A patent/NZ259597A/en unknown
- 1993-12-20 WO PCT/SE1993/001090 patent/WO1994015959A1/en not_active Application Discontinuation
- 1993-12-20 KR KR1019950702750A patent/KR960700269A/ko not_active Application Discontinuation
- 1993-12-20 PL PL93309778A patent/PL309778A1/xx unknown
- 1993-12-24 IL IL10816993A patent/IL108169A0/xx unknown
- 1993-12-27 IS IS4115A patent/IS4115A/is unknown
-
1994
- 1994-01-04 MX MX9400255A patent/MX9400255A/es unknown
- 1994-01-04 US US08/176,938 patent/US5602099A/en not_active Expired - Fee Related
- 1994-01-05 AP APAP/P/1994/000605A patent/AP508A/en active
- 1994-01-05 SI SI9400005A patent/SI9400005A/sl unknown
- 1994-01-05 YU YU394A patent/YU394A/sh unknown
- 1994-01-05 CN CN94100129A patent/CN1096515A/zh active Pending
- 1994-01-05 ZA ZA9455A patent/ZA9455B/xx unknown
- 1994-11-03 EE EE9400326A patent/EE9400326A/xx unknown
-
1995
- 1995-06-29 LV LVP-95-197A patent/LV10962B/en unknown
- 1995-07-04 FI FI953302A patent/FI953302A/sv unknown
- 1995-07-04 NO NO952650A patent/NO952650L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JPH08505386A (ja) | 1996-06-11 |
| SK83995A3 (en) | 1996-09-04 |
| IS4115A (is) | 1994-07-06 |
| IL108169A0 (en) | 1994-04-12 |
| FI953302A0 (sv) | 1995-07-04 |
| EE9400326A (et) | 1996-04-15 |
| WO1994015959A1 (en) | 1994-07-21 |
| EP0678099A1 (en) | 1995-10-25 |
| US5602099A (en) | 1997-02-11 |
| PL309778A1 (en) | 1995-11-13 |
| CA2152380A1 (en) | 1994-07-21 |
| SI9400005A (en) | 1994-12-31 |
| AU681372B2 (en) | 1997-08-28 |
| CZ171195A3 (en) | 1996-09-11 |
| AU5844894A (en) | 1994-08-15 |
| HUT72597A (en) | 1996-05-28 |
| FI953302A (sv) | 1995-07-04 |
| LV10962A (lv) | 1995-12-20 |
| KR960700269A (ko) | 1996-01-19 |
| NO952650D0 (no) | 1995-07-04 |
| MX9400255A (es) | 1994-07-29 |
| NO952650L (no) | 1995-08-30 |
| AP9400605A0 (en) | 1994-01-31 |
| SE9300012D0 (sv) | 1993-01-05 |
| YU394A (sh) | 1997-07-31 |
| ZA9455B (en) | 1994-07-05 |
| CN1096515A (zh) | 1994-12-21 |
| HU9502041D0 (en) | 1995-09-28 |
| AP508A (en) | 1996-07-22 |
| NZ259597A (en) | 1996-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LV10962B (en) | New peptides | |
| EP1163263B1 (en) | Dalda analogs and their use | |
| US5455230A (en) | Delta opioid receptor antagonists and their use as analgesic agents | |
| US5811400A (en) | Peptide derivatives with δ opioid receptor antagonist or mixed μ agδ antagonist effects | |
| Misicka et al. | Topographical requirements for delta opioid ligands: presence of a carboxyl group in position 4 is not critical for deltorphin high delta receptor affinity and analgesic activity | |
| JP2633369B2 (ja) | ペプチド | |
| US5733881A (en) | Opioid peptide antagonists | |
| US5786447A (en) | Opioid peptide analogs | |
| AU691630C (en) | New opioid peptide antagonists | |
| EP0777682A1 (en) | New opioid peptide antagonists |